1 identifying cancer patients from GC-patterned fragment ends of cell-free DNA

Samuel D. Curtis^{a,b,c,d,e}, Mahmoud Summers^{a,b,c,d}, Joshua D. Cohen^{a,b,c,d,f}, Yuxuan Wang^{a,b,c,d}, Nadine
Nehme^{a,b,c,d}, Maria Popoli^{a,b,c,d}, Janine Ptak^{a,b,c,d}, Natalie Sillman^{a,b,c,d}, Lisa Dobbyn^{a,b,c,d}, Adam Buchanan^g,
Jeanne Tie^{h,i,j}, Peter Gibbs^{h,i,k}, Lan T. Ho-Pham^{l,k}, Bich N. H. Tran^{m,n}, Shibin Zhou^{a,b,c,d}, Chetan
Bettegowda^{a,b,c,o}, Anne Marie Lennon^{b,c,p}, Ralph H. Hruban,^{b,c,q}, Kenneth W. Kinzler^{a,b,c}, Nickolas
Papadopoulos^{a,b,c}, Bert Vogelstein^{a,b,c,d}, Christopher Douville^{a,b,c,d,1}

⁷aLudwig Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287; ^bSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287; ^cSol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287; ^dHoward Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287; ^cDepartment of Pharmacology and Molecular Science, Johns Hopkins School of Medicine, Baltimore, MD 21287; ^dHoward Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287; ^bDepartment of Pharmacology and Molecular Science, Johns Hopkins School of Medicine, Baltimore, MD 21287; ^fDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218; ^gGenomic Medicine Institute, Geisinger, Danville, PA 17822; ^hDivision of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; ⁱDepartment of Medical Oncology, Western Health, Melbourne, Australia; ⁱFaculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia; ⁱBourne, Australia; ^kDepartment of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia; ⁱBioMedical Research Center, Pham Ngoc Thach University of Medicine; ^mSaigon Precision Medicine Research Center, Vietnam; ⁿUniversity of New South Wales, Australia, ^oDepartment of Neurosurgery, Johns Hopkins Medical Institutions, Baltimore, MD 21287, ^pDepartment of Medical, Johns Hopkins Medical Institutions, Baltimore, MD 21287, ^qDepartment of Medical Institutions, Baltimore, MD 21287, ^qDepartment of Medical Institutions, Baltimore, MD 21287, ^pDepartment of Medical, Johns Hopkins Medical Institutions, Baltimore, MD 21287, ^qDepartment of Medical, Johns Hopkins Medical Institutions, Baltimore, MD 21287, ^qDepartment of Medical, Johns Hopkins Medical Institutions, Baltimore, MD 21287, ⁿDepartment of Medicine, Johns Hopkins Medical Institutio

17 ABSTRACT: One of the most intriguing characteristics of cell-free DNA (cfDNA) from plasma is the 18 sequence at the ends of the fragments. Previous studies have shown that these end-sequences are 19 somewhat different in cancer patients than in healthy individuals. While investigating this characteristic, we 20 noticed that the bases at the 5'-ends of a double-stranded fragment were highly correlated with the GC 21 content of that particular fragment. This led us to develop a method, called MendSeqS (Modified End-based 22 sequencing System), that incorporates the correlation between end-motifs and GC content into the analysis 23 of shallow (0.5x) whole genome sequencing (WGS). When applied to plasma samples, MendSeqS was 24 able to classify patients with a sensitivity of 96% at 98% specificity in a cohort comprised of 107 individuals 25 evaluated in our laboratory (43 with cancer and 64 without). In cohorts evaluated in three other laboratories, 26 comprising a total of 401 individuals (193 with cancer and 208 without), MendSeqS achieved a sensitivity 27 of 87% at 98% specificity. MendSeqS could in principle be combined with other methods of cfDNA analysis 28 to enhance cancer detection.

29 INTRODUCTION:

The earlier detection of cancer has the potential to substantially reduce cancer morbidity and mortality 30 because all cancer treatments are more successful when there's a lower tumor burden in the patient¹⁻². The 31 32 evaluation of cell-free DNA (cfDNA) from plasma is one of the most promising approaches for such earlier 33 detection. Numerous ways to use cfDNA have been described in the literature. Genetic alterations in cfDNA 34 - such as mutations or copy number alterations - have been extensively used for this purpose. Epigenetic 35 alterations, in particular changes in DNA methylation, have also been used to identify patients with cancer³⁻ 36 ⁶. Other types of epigenetic changes, reflecting chromatin organization rather than covalent modifications of DNA, have more recently gained attention^{3, 7-12}. Because DNA is always wrapped in nucleosomes, 37 whether in the cell or in the circulation, changes in chromatin structure result in changes of the fragments 38 39 produced by nucleases in the cell of origin or in the circulation^{11, 13-14}. This gives rise to different 40 fragmentation patterns as well as differences in fragment sizes or the sequences at the ends of fragments. 41 Because epigenetics, rather than genetics, is responsible for cell differentiation epigenetic patterns in

- 42 plasma cfDNA can often reveal the cell of origin of the fragments.
- 43 Though the results to date of these cfDNA-based technologies are promising, further research to increase
- the sensitivity of cancer detection while maintaining high specificity is a research and clinical priority. We
- 45 here report a new heuristic, inspired by previous studies of cfDNA fragmentation patterns in cancer patients,
- 46 particularly studies on fragment end-motifs, for classifying patients based on data from shallow whole
- 47 genome sequencing^{13, 15-17}.
- 48

49 **RESULTS**:

50 We began by evaluating 43 cancer patients and 64 healthy individuals of similar age (Cohort 1, Table 1)

51 Whole genome sequencing was performed on the cfDNA of each of these patients (Methods) to an average

52 depth of 17 million high quality reads (~0.5x genome coverage). Two key observations about the sequences


53 of the bases at the ends of fragments were made during this initial evaluation, which led us to evaluate

54 more patients and develop algorithms for classifying cancer patients based on them.

55 **Observation 1: End-motif frequency is influenced by local GC content**

56 We first found that the frequencies of trimers at the 5'-ends of fragments correlated with the GC content of 57 the entire fragment (i.e., the 3 base pairs at each of the two ends plus the ~70 to 350 bp (average ~170 bp) 58 between the trimers). We made similar observations with the two bases at the ends (dimers) or the four 59 bases at the ends (tetramers), but we focused on trimers in this study. We noticed a few general trends 60 dependent on the GC content of the particular trimer (Fig. 1 and Supplementary Data 1). The frequency of 61 fragments with ends containing two A:T bp and one G:C bp were negatively correlated with the GC content 62 of the entire fragment (e.g., Fig. 1A). Conversely, the frequency of fragments with ends containing one A:T 63 bp and two G:C bp were *positively* correlated with the GC content of the entire fragment (e.g., Fig. 1B). 64 Figure 1C illustrates the trend when the trimer composition was extreme, with G:C bp at all three positions. 65 Though a positive correlation with of the frequency of the extreme type of trimer and the GC content of the 66 entire fragment was still evident, the relationship was exponential rather than linear. These trends were 67 observed in plasma cfDNA derived from healthy individuals as well as from cancer patients in Cohort 1 (Fig. 1A to 1D) as well as in publicly available data¹⁸ (Fig 1 E to 1H). The GC-dependent frequencies of all 64 68 trimers in the cohorts used in this study are presented in Supplementary Table 2. To test whether these 69 70 trends were specific to cell-free DNA, we performed in silico shearing of the hg19 reference genome. When 71 the human genome was randomly sheared to the same fragment size distribution as cfDNA, the trends in 72 end-motif trimer frequency as a function of GC content were similar to those of actual cfDNA (Fig 1 I to 1L).

- 73
- 74



MendSeqS, Curtis et al., Page 2

Figure 1. Correlations between end-motif frequencies and GC-contents of the fragment from which the ends were derived. (A-D) End-motif trimer frequencies in healthy individuals and cancer patients in Cohort 1. The dotted lines represent the frequencies of the indicated end-motif trimers regardless of the GC content of the fragment from which the trimer was derived and are therefore horizontal lines in this plot. The solid lines represent the frequencies of the indicated trimers as a function of the GC content (x-axis) of the fragments containing them. (E-H) Similar patterns were observed in cfDNA samples from Cohort 3 and in in silico-generated fragments from the hg19 genome (I-L).

76

99

77 Observation 2: Binning end-motifs by fragment GC content improves the distinction between 78 healthy individuals and cancer patients

It has previously been demonstrated that the frequencies of trimers at the 5'-ends of cfDNA fragments from 79 80 healthy individuals is different than those derived from patients with cancer^{13, 17, 19-20}. In this study, we observed that cancer-specific differences in end-motifs are substantially more pronounced if the GC content 81 82 of the entire fragment is taken into account. This is illustrated in Fig. 2 for each of the four trimers shown in 83 Fig. 1. For each trimer, the frequency of fragments containing that trimer was determined from the WGS 84 data of Cohort 1. Using the frequencies in the 64 healthy individuals in this cohort as a reference distribution, 85 Z-scores for each sample in Cohort 1 could be calculated, with a Z-score of zero corresponding to the 86 average frequency of that trimer in the healthy individuals. The average Z-scores for the 43 cancer patients 87 in Cohort 1 are represented by the horizontal blue lines in Fig. 2. Similarly, Z-scores could be calculated for 88 each trimer present in bins of fragments with similar GC contents. Sixty such Z-scores were obtained for 89 each trimer, corresponding to bins of 20% to 21% GC content, 21% to 22%, etc. all the way up to 79% to 90 80%. The average Z-scores for the 43 cancer patients in Cohort 1, as a function of the GC content of the 91 underlying fragment (x-axis) are represented by the orange lines in Fig. 2.

92 As an example, with trimer TGT the average Z-score was -0.619 without consideration of GC (blue line in 93 Fig. 2A) while the average Z-scores ranged from -2.0 in fragments with a GC content of 29% to +0.6 in 94 fragments with a GC content of 60% (orange line in Fig. 2A). The maximum absolute Z-score for the TGT

95 trimer, when considering GC contents, was three times as high as the Z-score for the same trimer when

96 GC contents were not considered. This translated to an improved distinction between cancer patients and 97

- healthy individuals with TGT trimers (Mann-Whitney p-values of 1.1e-11 vs. 0.002 with and without GC
- 98 content consideration, respectively; Supplementary Table 2).





Figure 2. Comparisons of end-motif trimer frequencies in cfDNA fragments from cancer patients and healthy individuals with or without consideration of GC content. Average Z-scores (lines) and 95% confidence intervals (shaded) are shown for the 22 cancer patients in Cohort 1, using the trimer frequencies in the 64 healthy individuals in Cohort 1 as references. (A) Z-scores for TGT; (B) Z-scores for GCG (C); Z-scores for GAG; (D) Z-scores for ATT.

100

101 The distinction between cancer patients and normal individuals was also observed with trimers GAG and 102 GCG, though the patterns were different (Fig. 2B, C). At low or high fragment GC contents, these trimers 103 displayed relatively low Z-scores, with no improvement in Z-scores evident after consideration of GC 104 content. However, at GC contents between 35% and 65%, there was a large increase in Z-scores when 105 GC contents were considered, with mean Z-scores as high as 5.9 and 3.5 for GCG and GAG, respectively 106 - as much as three-fold higher than obtained without consideration of GC content. As with the TGT trimer, 107 this translated to an improved distinction between samples from cancer patients and healthy individuals 108 (Mann-Whitney p-values of 8.3e-14 vs. 5.7e-5 with and without GC content consideration, respectively, for 109 GCG; 3.3e-14 with GC content vs. 3.3e-8 with and without GC content consideration, respectively, for GAG, 110 Supplementary Table 2).

Fig 2D illustrates a trimer (ATT) in which there is relatively little change in the Z-scores as a function of GC content of the fragment. However, there were still cancer-specific differences in the frequencies of ATT end-motifs, with a max z-score of 1.55 with GC content consideration and mean Z-score of 0.77 without GC content consideration (Mann-Whitney p-values of 5.4e-05 and 0.006 with and without GC content consideration, respectively; Supplementary Table 2).

116 A classifier. Based on the two observations described above, it was clear that a subset of trimers exhibited 117 GC-dependent, cancer-associated differences in frequencies. To incorporate the relationship between GC 118 content and trimer frequencies into a classifier, we performed feature selection on the basis of their mutual 119 information and Mann-Whitney p-values using leave-one-out cross validation. We thereby selected an 120 average of 2293 features from the set of 3840 possible features (64 trimers x 60 GC intervals; Table 2 and Methods). These 2293 features included all 64 trimers and an average of 36 GC contents per trimer. To 121 122 avoid information leakage, all feature selections were performed within each fold of cross-validation. This 123 heuristic was named MendSeqS, for Modified end-based Sequencing System. For comparison, we 124 selected 47 trimers using the same criteria (Mutual Information and Mann Whitney p-values) without 125 considering GC content of the underlying fragments, referring to this conventional heuristic as EndSegS 126 (Table 3). We then used logistic regression to assign weights (coefficients) to each of the selected features 127 in MendSeqS and EndSeqS. Logistic regression yielded a single score for each heuristic in each patient 128 (Fig. 3A). The most obvious difference between the performance of MendSeqS and EndSeqS was the 129 tighter distribution of scores in MendSeqS (Fig. 3A). This translated to a lower binary cross-entropy in 130 MendSeqS (0.16) than in EndSeqS (0.21) (Methods). MendSeqS also was significantly more accurate than EndSeqS in ROC analysis (p-value of 0.015, Venkatraman's test²², Fig. 3B). This improvement was 131 particularly significant in the high specificity realm most important for earlier detection, where MendSeqS 132 achieved a sensitivity of 95% (41/43) at 98% specificity whereas EndSeqS achieved a sensitivity of only 133 134 84% (36/43) (p-value of 0.024, Pepe's test²³, Fig. 3C).



135

Figure 3. Performance of MendSeqS and EndSeqS on Cohort 1. (A) Box and swarm plots display the scores for MendSeqS and EndSeqS from leave one-out cross-validation. (B) Comparison of ROC curves from MendSeqS and EndSeqS during cross-validation (C) ROC at high specificity, representing the upper left part of (B).

136

Analysis of other WGS datasets. We then sought to see if MendSeqS could be applied to DNA samples that had been prepared, amplified, and sequenced in other laboratories. For this purpose, we employed 401 samples (193 with cancer, 208 without cancer) deposited in the FinaleDB public database¹⁸ (called Cohort 2,Table 4) from three separate studies, each using different technologies^{9, 11, 24}. The cancer types represented in Cohort 2 were different than those in Cohort 1 (compare Table 1 with Table 4).

The first question addressed was whether the two basic observations that formed the rationale for MendSeqS were apparent in Cohort 2. With respect to Observation 1, the data in Figures 1E-H show a strong GC-dependence of the frequencies of the same four trimers illustrated in Figs 1A-D, and this was true for all 64 trimers (Supplementary Data 1).

With respect to Observation 2, the key question was whether MendSeqS could improve the classification of cancer samples in Cohort 2 over that achieved with EndSeqS. Because the sample types and methods used for DNA purification, library preparation, and sequencing analysis were heterogeneous in Cohort 2 and different than in Cohort 1, we derived new features and coefficients for Cohort 2 and evaluated them using leave one-out cross-validation (just as done for Cohort 1). For MendSeqs in Cohort 2, we selected an average of 2414 features (64 trimers x average of 38 GC contents per primer) from the set of 3840 possible features (Table 5). For EndSeqS, we selected all 51 using the same criteria (Table 6, Methods).

Dot plots of the scores of the four cancer types obtained with MendSeqS and EndSeqS are plotted in Fig. 4A, where the tighter distribution of MendSeqS scores was again observed. MendSeqS also was more accurate than EndSeqS in ROC analysis (p-value of 0.054, Venkatraman's test²², Fig. 4B). This improvement was particularly significant in the high specificity realm most important for earlier detection, where MendSeqS achieved a sensitivity of 87% (168/193) at 98% specificity, whereas EndSeqS was less sensitive at the same specificity (68% [131/193], p-value of 0.0087, Pepe's test²³, Fig. 4C).

159




Figure 4. Performance of MendSeqS and EndSeqS on Cohort 2. (A) Scores from leave one-out cross-validation for four tumor types and healthy samples are shown.. (B) ROC curves displaying the performance across the 10 iterations of cross-validation.(C) ROC at high specificity, taken from the upper left part of (B).

162 Discussion

160

161

The results described above demonstrate that the distributions of trimers at the 5' ends of cfDNA fragments are influenced by the GC content of the fragment from which those ends were derived. Moreover, taking this GC dependency into account can magnify the differences in trimer frequency between cancer patients and healthy individuals, resulting in improved classification performance.

167 The GC dependence of trimers was observed in samples from both cancer patients and healthy controls. 168 The similarity of the trends as seen in cell-free DNA and in silico fragmentation experiments indicate that 169 these trends reflect the influence of local GC content on the frequency of each end-motif (Fig. 1I-L; 170 Methods). Moreover, while the overall shapes of the curves relating to end-motif frequency and fragment 171 GC content are observed in experimental data (Cohorts 1 and 3), and in silico fragmentation, their 172 magnitude is different. Note, for example, that the y-axes are different in Fig 1A, 1E, and 1I. Previous studies have shown that the distribution of fragment-end motifs are influenced by the activity of sequence specific 173 nucleases such as DNASE1, DNASE1L3, and DFFB²⁵⁻²⁶ as well as chromatin organization, with DNA 174 wrapped around nucleosomes less susceptible to cleavage than internucleosomal regions^{11, 27}. Our results 175 176 illustrate that the frequency of end-motifs is also heavily influenced by GC content of the region itself, 177 implying that phenomena such as PCR biases and copy number changes may add significant noise to the overall end-motif frequency. Through the binning of end-motifs by GC content, it is possible to disaggregate 178 the signal derived from fragments of varying GC content, allowing MendSeqS to overcome these 179 180 confounders.

Several prior studies have documented the utility of cancer-specific differences in trimers or other motifs at the ends of cfDNA fragments for cancer detection^{13, 17, 19-20}. MendSeqS amplifies these differences, as documented by higher Z-scores, p-values, and mutual information when GC content of fragments are considered (Supplementary Table 2). There are at least three possible explanations for these cancerspecific differences. The activities of sequence-specific nucleases that produce cfDNA fragments in neoplastic cells may not be identical to those in non-neoplastic cells. For example, DFFB, associated with

187 certain forms of cell death, could be more active in a subset of neoplastic cells^{3, 25-26, 28}. Second, DNA from 188 neoplastic cells could be more fragmented as a result of unrepaired DNA damage by exogenous or 189 endogenous sources of DNA damage (e.g. chemical insults, radiation, free radicals, topological changes) 190 which may lead to changes in the distribution of end-motifs. ^{8, 13, 20}. Third, differences in chromatin structure 191 between neoplastic and non-neoplastic cells are known to alter the fragmentation patterns of cell-free DNA 192 and could explain both cell-type specific and cancer-specific changes ^{7-8, 11, 14, 29-31}. Further research will be 193 required to determine the relative importance of these three potential explanations.

Note that in the proposed explanations above we are *assuming* that the cancer-specific differences in trimers are the result of contributions of cfDNA derived from neoplastic cells. In fact, neither our data nor prior evidence provide unequivocal evidence that the fragments whose ends give rise to the cancer-specific signal are actually derived from cancer cells. They could be derived from non-cancer cells of the organ giving rise to the cancer, or from leukocytes or other cells that are simply associated with cancer.

199 Our study of course has limitations. Among them, our cohorts were relatively small so the confidence limits 200 in the estimates of sensitivity and specificity derived from the ROC curves are relatively wide. Second, in 201 the ideal situation, the selected features and the logistic regression coefficients associated with each feature 202 should be broadly applicable to all cohorts. However, when we applied the features and coefficients derived 203 from the analysis of data generated in other laboratories (Cohort 2) to those generated in our laboratory 204 (Cohort 1), the MendSeqS sensitivity at 95% specificity dropped from 92% to 23.1%. This drop in sensitivity 205 was also observed in EndSeqS, dropping from 89% to 18.1% when features from Cohort 1 rather than 206 Cohort 2 were used. Therefore, the decreased performance was not likely to be a result of the new 207 heuristics employed in MendSeqS. The most obvious basis for the difference in performance is that the sample preparation, DNA library construction, and sequencing methods - factors that are known to 208 209 influence characteristics of cell-free DNA³²⁻³⁵ – used in Cohort 2 were different than those used to in Cohort 210 1. The enzymes used to make WGS libraries often employ nucleases and polymerases that can alter the bases at the ends of fragments in preparation for ligation, so this explanation is plausible. If true, it would 211 212 suggest that the parameters for GC adjustment used in a training set should be derived from control libraries 213 made identically to those used in the validation set. However, it is also possible that these performance 214 differences were representative of differences between tumor types in Cohort 2 (Liver, Lung, Pancreas, 215 and Colorectal) compared to Cohort 1 (predominately Colorectal), or to other confounders. Regardless, studies with more patients, and with different types of library constructions on the same patients, should be 216 217 able to address this issue in the future.

In summary, we demonstrate that the frequency and cancer-specificity of a cfDNA fragment end-motif are correlated with the GC content of the fragment from which the was derived. We anticipate that the principles on which MendSeqS is based can be incorporated into the analysis of cfDNA in general and can serve as an adjunct to other assays performed on the same cfDNA, such as mutations, methylation, fragment length, and chromatin accessibility.

223 <u>Methods</u>

224 Plasma Collection and DNA Collection

This study was approved by the Institutional Review Boards for Human Research at participating institutions in compliance with the Health Insurance Portability and Accountability Act. All the participants provided written informed consent in accordance with the principles of the Declaration of Helsinki. DNA was purified from an average of 1 to 10 mL of plasma using either a QIASymphony circulating DNA kit (cat # 1091063) or a BioChain Cell-free DNA Extraction kit (Cat # K5011625).

- 230 Library Preparation and Sequencing
- All libraries were prepared as described in ref. ³⁶. Barcoded libraries were sequenced using 75 bp paired-
- end runs (150 cycles) on either Illumina HiSeq 4000 or Novaseq 6000 platforms to an average depth of 17
- 233 million molecules. Adapters and UMIs were trimmed using cutadapt³⁷ and trimmed sequences were aligned

to the hg19 genome using bowtie2³⁸ in paired-end mode. Reads were filtered for a MAPQ>1 and duplicates
 were removed using unique molecular identifiers (UMIs). Paired-end reads that did not have proper
 orientation or did not have paired-end support were removed.

237 Fragment-End Analysis

Fragmentation data was collected from filtered SAM files. For each pair of reads the fragment start, end, and strand alignment was determined. Bedtools³⁹ was then used to sort fragments and extract the full insert sequence using the hg19 reference genome. GC content for each insert was then calculated using all bases of the aligned sequence.

For every unique molecule the first (5') and last (3') nucleotides of the fragment sequence were evaluated and the frequency of each motif at each end was determined. Our library preparation either degrades the 3' end of the original DNA duplex fragment when there is a 3'-overhang or fills-in a 5' overhang with the compliment of the 3' strand. We therefore used the end-motif (trimer) itself when the sequence read aligned to the reference strand of the genome, and the reverse compliment of the trimer when the sequence read aligned with the reverse compliment of the reference strand.

We binned each fragment based on the GC content of the sequence of the entire aligned read; when only part of a read aligned to the reference genome, it was discarded. GC bins extended from 20% to 21% GC, 21% to 22% GC, etc. up to 79 to 80% GC. Thus there were 60 possible bins and 64 possible trimers, for a total of 3840 possible features used for MendSeqS.

252 In silico fragmentation of the hg19 genome

We extracted fragments from 74 healthy controls and placed them randomly throughout the hg19 genome using the bedtools random function³⁹. For example, if sample A had 2000 fragments of length X we placed 2000 fragments of length X randomly throughout the hg19 genome.

256 Analysis of FinaleDB samples

Fragmentation data was downloaded for 352 patients from the FinaleDB database¹⁸. Data files were downloaded in sorted tsv format and contained fragment-end positioning (chr,start,end) and strand alignment. Fragment-end analysis was performed as described above.

260 Classification Algorithm

261 For each potential feature, we used the data within the training set (all but one of the samples) to create a

262 StandardScaler model (sklearn) to standardize features by removing the mean and scaling to unit variance.

263 Next, we evaluated (1) the mutual information between feature values and cancer status and (2) the Mann-

Whitney p-value for feature values of healthy controls *vs.* cancer samples (Tables 2, 3, 5, and 6). To remove uninformative features, we filtered for features that had either (a) mutual information greater than 0.05 or

(b) a p-value that remained statistically significant (i.e., < E-5) after Bonferonni correction (α =0.05). Logistic

regression was then used to determine the coefficient of each feature that surpassed these thresholds.

Finally, these coefficients were used to score the left out sample in each fold of cross-validation. Note that both feature selection and coefficient determination were determined in each fold of cross-validation to

avoid data leakage during feature selection²¹. After completing all folds, we calculated the binary cross-

271 entropy, AUROC and sensitivity at 98% specificity. This workflow was identical for both MendSeqS and

- 272 EndSeqS.
- 273 Code Availability

274 Scripts for analyzing bed files and evaluating logistic regressions are available under a GNU 3.0 public

- 275 license at https://github.com/sdcurtis/LudwigCenterBaltimore/tree/main
- 276

277

278 Data availability

The sequencing data generated in this study can be obtained from the European Genome–phenome Archive (accession number EGAS00001006418)

281 Conflicts of Interest

282 BV, KWK, & NP are founders of Thrive Earlier Detection, an Exact Sciences Company. KWK, NP, & CD 283 are consultants to Thrive Earlier Detection. BV, KWK, NP, SZ, and CD hold equity in Exact Sciences. BV, 284 KWK, NP, and SZ, are founders of or consultants to and own equity in ManaT Bio., Haystack Oncology, 285 Neophore, CAGE Pharma and Personal Genome Diagnostics. NP is consultant to Vidium. PG and JT are 286 consultants to Haystack Oncology. BV is a consultant to and holds equity in Catalio Capital Management SZ has a research agreement with BioMed Valley Discoveries, Inc. CB is a consultant to Depuy-Synthes, 287 288 Bionaut Labs, Haystack Oncology and Galectin Therapeutics. CB is a co-founder of OrisDx. The companies 289 named above, as well as other companies, have licensed previously described technologies related to the 290 work described in this paper from Johns Hopkins University. BV, KWK, NP, JDC, and CD are inventors on 291 some of these technologies. Licenses to these technologies are or will be associated with equity or royalty 292 payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described 293 in this paper may be filed by Johns Hopkins University. The terms of all these arrangements are being 294 managed by Johns Hopkins University in accordance with its conflict of interest policies.

295 Funding

296 This work was supported by The Lustgarten Foundation for Pancreatic Cancer Research, The Virginia and

297 D.K. Ludwig Fund for Cancer Research, The Conrad N. Hilton Foundation, The Sol Goldman Charitable

- 299 GM136577, U01 CA06973, T32 GM135083, and T32 GM007814).
- 300 References
- 301

Vogelstein, B.; Papadopoulos, N.; Velculescu Victor, E.; Zhou, S.; Diaz Luis, A.; Kinzler Kenneth, W.,
 Cancer Genome Landscapes. *Science* **2013**, *339* (6127), 1546-1558.

Hubbell, E.; Clarke, C. A.; Aravanis, A. M.; Berg, C. D., Modeled Reductions in Late-stage Cancer
 with a Multi-Cancer Early Detection Test. *Cancer Epidemiology, Biomarkers & Prevention* 2021, *30* (3),
 460-468.

Lo, Y. M. D.; Han Diana, S. C.; Jiang, P.; Chiu Rossa, W. K., Epigenetics, fragmentomics, and topology
 of cell-free DNA in liquid biopsies. *Science* 2021, *372* (6538), eaaw3616.

Galardi, F.; Luca, F.; Romagnoli, D.; Biagioni, C.; Moretti, E.; Biganzoli, L.; Leo, A. D.; Migliaccio, I.;
 Malorni, L.; Benelli, M., Cell-Free DNA-Methylation-Based Methods and Applications in Oncology.
 Biomolecules **2020**, *10* (12).

Oxnard, G. R.; Klein, E. A.; Seiden, M. V.; Hubbell, E.; Venn, O.; Jamshidi, A.; Zhang, N.; Beausang,
 J. F.; Gross, S.; Kurtzman, K. N.; Fung, E. T.; Allen, B.; Fields, A. P.; Liu, H.; Sekeres, M. A.; Richards, D. A.;
 Yu, P. P.; Aravanis, A. M.; Hartman, A. R.; Liu, M. C., Simultaneous multi-cancer detection and tissue of
 origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA). *Annals of*

- 316 Oncology **2019,** 30.
- Moss, J.; Magenheim, J.; Neiman, D.; Zemmour, H.; Loyfer, N.; Korach, A.; Samet, Y.; Maoz, M.;
 Druid, H.; Arner, P.; Fu, K. Y.; Kiss, E.; Spalding, K. L.; Landesberg, G.; Zick, A.; Grinshpun, A.; Shapiro, A. M.

J.; Grompe, M.; Wittenberg, A. D.; Glaser, B.; Shemer, R.; Kaplan, T.; Dor, Y., Comprehensive human cell-

J.; Grompe, M.; Wittenberg, A. D.; Glaser, B.; Shemer, R.; Kapian, T.; Dor, Y., Comprehensive human cell-

type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nat Commun*

321 **2018**, *9* (1), 5068.

Ding, S. C.; Lo, Y. M. D., Cell-Free DNA Fragmentomics in Liquid Biopsy. *Diagnostics (Basel)* **2022**,

322

7.

323 12 (4). 324 8. Esfahani, M. S.; Hamilton, E. G.; Mehrmohamadi, M.; Nabet, B. Y.; Alig, S. K.; King, D. A.; Steen, C. 325 B.; Macaulay, C. W.; Schultz, A.; Nesselbush, M. C.; Soo, J.; Schroers-Martin, J. G.; Chen, B.; Binkley, M. S.; 326 Stehr, H.; Chabon, J. J.; Sworder, B. J.; Hui, A. B. Y.; Frank, M. J.; Moding, E. J.; Liu, C. L.; Newman, A. M.; 327 Isbell, J. M.; Rudin, C. M.; Li, B. T.; Kurtz, D. M.; Diehn, M.; Alizadeh, A. A., Inferring gene expression from 328 cell-free DNA fragmentation profiles. Nature Biotechnology 2022, 40 (4), 585-597. 329 9. Cristiano, S.; Leal, A.; Phallen, J.; Fiksel, J.; Adleff, V.; Bruhm, D. C.; Jensen, S. Ø.; Medina, J. E.; 330 Hruban, C.; White, J. R.; Palsgrove, D. N.; Niknafs, N.; Anagnostou, V.; Forde, P.; Naidoo, J.; Marrone, K.; 331 Brahmer, J.; Woodward, B. D.; Husain, H.; van Rooijen, K. L.; Ørntoft, M.-B. W.; Madsen, A. H.; van de 332 Velde, C. J. H.; Verheij, M.; Cats, A.; Punt, C. J. A.; Vink, G. R.; van Grieken, N. C. T.; Koopman, M.; Fijneman, 333 R. J. A.; Johansen, J. S.; Nielsen, H. J.; Meijer, G. A.; Andersen, C. L.; Scharpf, R. B.; Velculescu, V. E., 334 Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 2019, 570 (7761), 385-389. 335 10. Ulz, P.; Perakis, S.; Zhou, Q.; Moser, T.; Belic, J.; Lazzeri, I.; Wolfler, A.; Zebisch, A.; Gerger, A.; 336 Pristauz, G.; Petru, E.; White, B.; Roberts, C. E. S.; John, J. S.; Schimek, M. G.; Geigl, J. B.; Bauernhofer, T.; Sill, H.; Bock, C.; Heitzer, E.; Speicher, M. R., Inference of transcription factor binding from cell-free DNA 337 338 enables tumor subtype prediction and early detection. Nat Commun 2019, 10 (1), 4666. 339 Snyder, M. W.; Kircher, M.; Hill, A. J.; Daza, R. M.; Shendure, J., Cell-free DNA Comprises an In Vivo 11. 340 Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell 2016, 164 (1-2), 57-68. 341 12. Mouliere, F., Enhanced detection of circulating tumor DNA by fragment size analysis. Science 342 Translational Medicine **2018**, 10. 343 13. Jiang, P.; Sun, K.; Peng, W.; Cheng, S. H.; Ni, M.; Yeung, P. C.; Heung, M. M. S.; Xie, T.; Shang, H.; 344 Zhou, Z.; Chan, R. W. Y.; Wong, J.; Wong, V. W. S.; Poon, L. C.; Leung, T. Y.; Lam, W. K. J.; Chan, J. Y. K.; 345 Chan, H. L. Y.; Chan, K. C. A.; Chiu, R. W. K.; Lo, Y. M. D., Plasma DNA End-Motif Profiling as a Fragmentomic 346 Marker in Cancer, Pregnancy, and Transplantation. Cancer Discov 2020, 10 (5), 664-673. 347 14. Zhu, G.; Guo, Y. A.; Ho, D.; Poon, P.; Poh, Z. W.; Wong, P. M.; Gan, A.; Chang, M. M.; Kleftogiannis, 348 D.; Lau, Y. T.; Tay, B.; Lim, W. J.; Chua, C.; Tan, T. J.; Koo, S. L.; Chong, D. Q.; Yap, Y. S.; Tan, I.; Ng, S.; 349 Skanderup, A. J., Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden. Nat 350 Commun 2021, 12 (1), 2229. 351 15. Budhraja, K. K.; McDonald, B. R.; Stephens, M. D.; Contente-Cuomo, T.; Markus, H.; Faroog, M.; 352 Favaro, P. F.; Connor, S.; Byron, S. A.; Egan, J. B.; Ernst, B.; McDaniel, T. K.; Sekulic, A.; Tran, N. L.; Prados, 353 M. D.; Borad, M. J.; Berens, M. E.; Pockaj, B. A.; LoRusso, P. M.; Bryce, A.; Trent, J. M.; Murtaza, M., Analysis

of fragment ends in plasma DNA from patients with cancer. *medRxiv* **2021**, 2021.04.23.21255935.

I6. Zhou, Z.; Cheng, S. H.; Ding, S. C.; Heung, M. M. S.; Xie, T.; Cheng, T. H. T.; Lam, W. K. J.; Peng, W.;
Teoh, J. Y. C.; Chiu, P. K. F.; Ng, C. F.; Jiang, P.; Chan, K. C. A.; Chiu, R. W. K.; Lo, Y. M. D., Jagged Ends of
Urinary Cell-Free DNA: Characterization and Feasibility Assessment in Bladder Cancer Detection. *Clin Chem* 2021, *67* (4), 621-630.

Markus, H.; Chandrananda, D.; Moore, E.; Mouliere, F.; Morris, J.; Brenton, J. D.; Smith, C. G.;
Rosenfeld, N., Refined characterization of circulating tumor DNA through biological feature integration. *Scientific Reports* 2022, *12* (1), 1928.

362 18. Zheng, H.; Zhu, M. S.; Liu, Y., FinaleDB: a browser and database of cell-free DNA fragmentation
 363 patterns. *Bioinformatics* 2021, *37* (16), 2502-2503.

Budhraja, K. K.; McDonald, B. R.; Stephens, M. D.; Contente-Cuomo, T.; Markus, H.; Farooq, M.;
 Favaro, P. F.; Connor, S.; Byron, S. A.; Egan, J. B.; Ernst, B.; McDaniel, T. K.; Sekulic, A.; Tran, N. L.; Prados,
 A. D. Barrad, M. L. Barrad, M. J. Barlai, B. A. Japanez, D. M. Barrad, J. M. Murtana, M. Anahusia

366 M. D.; Borad, M. J.; Berens, M. E.; Pockaj, B. A.; LoRusso, P. M.; Bryce, A.; Trent, J. M.; Murtaza, M., Analysis

of fragment ends in plasma DNA from patients with cancer. *medRxiv* **2021**.

368 20. Moldovan, N.; van der Pol, Y.; van den Ende, T.; Boers, D.; Verkuijlen, S.; Creemers, A.; Ramaker,

J.; Vu, T.; Fransen, M. F.; Pegtel, M.; Bahce, I.; van Laarhoven, H.; Mouliere, F., Genome-wide cell-free DNA
 termini in patients with cancer. *medRxiv* 2021.

Kaufman, S.; Rosset, S.; Perlich, C.; Stitelman, O., Leakage in data mining: Formulation, detection,
and avoidance. *ACM Trans. Knowl. Discov. Data* December 2012, 6 (4), 1-21.

373 22. Venkatraman, E. S., A Permutation Test to Compare Receiver Operating Characteristic Curves.
374 *Biometrics* 2000, *56* (4), 1134-1138.

Gu, W.; Pepe, M., Measures to Summarize and Compare the Predictive Capacity of Markers. *The International Journal of Biostatistics* 2009, 5 (1).

Jiang, P.; Chan, C. W.; Chan, K. C.; Cheng, S. H.; Wong, J.; Wong, V. W.; Wong, G. L.; Chan, S. L.;
Mok, T. S.; Chan, H. L.; Lai, P. B.; Chiu, R. W.; Lo, Y. M., Lengthening and shortening of plasma DNA in
hepatocellular carcinoma patients. *Proc Natl Acad Sci U S A* **2015**, *112* (11), E1317-25.

Han, D. S. C.; Ni, M.; Chan, R. W. Y.; Chan, V. W. H.; Lui, K. O.; Chiu, R. W. K.; Lo, Y. M. D., The
Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. *The American Journal of Human Genetics* 2020, *106* (2), 202-214.

26. Serpas, L.; Chan Rebecca, W. Y.; Jiang, P.; Ni, M.; Sun, K.; Rashidfarrokhi, A.; Soni, C.; Sisirak, V.; Lee, W.-S.; Cheng Suk, H.; Peng, W.; Chan, K. C. A.; Chiu Rossa, W. K.; Reizis, B.; Lo, Y. M. D., Dnase113 deletion causes aberrations in length and end-motif frequencies in plasma DNA. *Proceedings of the National Academy of Sciences* **2019**, *116* (2), 641-649.

Widlak, P.; Li, P.; Wang, X.; Garrard, W. T., Cleavage preferences of the apoptotic endonuclease
DFF40 (caspase-activated DNase or nuclease) on naked DNA and chromatin substrates. *J Biol Chem* 2000,
275 (11), 8226-32.

Biology International 2019, 43 (6), 582-592.

392 29. Klemm, S. L.; Shipony, Z.; Greenleaf, W. J., Chromatin accessibility and the regulatory epigenome.
393 Nat Rev Genet 2019, 20 (4), 207-220.

394 30. Corces, M. R.; Granja Jeffrey, M.; Shams, S.; Louie Bryan, H.; Seoane Jose, A.; Zhou, W.; Silva Tiago, 395 C.; Groeneveld, C.; Wong Christopher, K.; Cho Seung, W.; Satpathy Ansuman, T.; Mumbach Maxwell, R.; 396 Hoadley Katherine, A.; Robertson, A. G.; Sheffield Nathan, C.; Felau, I.; Castro Mauro, A. A.; Berman 397 Benjamin, P.; Staudt Louis, M.; Zenklusen Jean, C.; Laird Peter, W.; Curtis, C.; null, n.; Greenleaf William, 398 J.; Chang Howard, Y.; Akbani, R.; Benz Christopher, C.; Boyle Evan, A.; Broom Bradley, M.; Cherniack 399 Andrew, D.; Craft, B.; Demchok John, A.; Doane Ashley, S.; Elemento, O.; Ferguson Martin, L.; Goldman 400 Mary, J.; Hayes, D. N.; He, J.; Hinoue, T.; Imielinski, M.; Jones Steven, J. M.; Kemal, A.; Knijnenburg Theo, 401 A.; Korkut, A.; Lin, D.-C.; Liu, Y.; Mensah Michael, K. A.; Mills Gordon, B.; Reuter Vincent, P.; Schultz, A.; 402 Shen, H.; Smith Jason, P.; Tarnuzzer, R.; Trefflich, S.; Wang, Z.; Weinstein John, N.; Westlake Lindsay, C.; 403 Xu, J.; Yang, L.; Yau, C.; Zhao, Y.; Zhu, J., The chromatin accessibility landscape of primary human cancers. 404 Science 2018, 362 (6413), eaav1898.

Thurman, R. E.; Rynes, E.; Humbert, R.; Vierstra, J.; Maurano, M. T.; Haugen, E.; Sheffield, N. C.;
Stergachis, A. B.; Wang, H.; Vernot, B.; Garg, K.; John, S.; Sandstrom, R.; Bates, D.; Boatman, L.; Canfield,
T. K.; Diegel, M.; Dunn, D.; Ebersol, A. K.; Frum, T.; Giste, E.; Johnson, A. K.; Johnson, E. M.; Kutyavin, T.;

408 Lajoie, B.; Lee, B.-K.; Lee, K.; London, D.; Lotakis, D.; Neph, S.; Neri, F.; Nguyen, E. D.; Qu, H.; Reynolds, A.

409 P.; Roach, V.; Safi, A.; Sanchez, M. E.; Sanyal, A.; Shafer, A.; Simon, J. M.; Song, L.; Vong, S.; Weaver, M.;

410 Yan, Y.; Zhang, Z.; Zhang, Z.; Lenhard, B.; Tewari, M.; Dorschner, M. O.; Hansen, R. S.; Navas, P. A.;

411 Stamatoyannopoulos, G.; Iyer, V. R.; Lieb, J. D.; Sunyaev, S. R.; Akey, J. M.; Sabo, P. J.; Kaul, R.; Furey, T. S.;

412 Dekker, J.; Crawford, G. E.; Stamatoyannopoulos, J. A., The accessible chromatin landscape of the human

413 genome. *Nature* **2012**, *489* (7414), 75-82.

414 32. Devonshire, A. S.; Whale, A. S.; Gutteridge, A.; Jones, G.; Cowen, S.; Foy, C. A.; Huggett, J. F., 415 Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency,

fragment size bias and quantification. *Analytical and Bioanalytical Chemistry* **2014**, *406* (26), 6499-6512.

417 33. Warton, K.; Graham, L.-J.; Yuwono, N.; Samimi, G., Comparison of 4 commercial kits for the 418 extraction of circulating DNA from plasma. *Cancer Genetics* **2018**, *228-229*, 143-150.

419 34. Diefenbach, R. J.; Lee, J. H.; Kefford, R. F.; Rizos, H., Evaluation of commercial kits for purification
420 of circulating free DNA. *Cancer Genetics* **2018**, *228-229*, 21-27.

421 35. Page, K.; Guttery, D. S.; Zahra, N.; Primrose, L.; Elshaw, S. R.; Pringle, J. H.; Blighe, K.; Marchese, S.

422 D.; Hills, A.; Woodley, L.; Stebbing, J.; Coombes, R. C.; Shaw, J. A., Influence of Plasma Processing on 423 Recovery and Analysis of Circulating Nucleic Acids. *PLOS ONE* **2013**, *8* (10), e77963.

424 36. Cohen, J. D.; Douville, C.; Dudley, J. C.; Mog, B. J.; Popoli, M.; Ptak, J.; Dobbyn, L.; Silliman, N.; 425 Schaefer, J.; Tie, J.; Gibbs, P.; Tomasetti, C.; Papadopoulos, N.; Kinzler, K. W.; Vogelstein, B., Detection of 426 low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. *Nature* 427 *biotechnology* **2021**, *39* (10), 1220-1227.

428 37. Martin, M., Cutadapt removes adapter sequences from high-throughput sequencing reads.
 429 *EMBnet.journal; Vol 17, No 1: Next Generation Sequencing Data Analysis* 2011.

430 38. Langmead, B.; Salzberg, S. L., Fast gapped-read alignment with Bowtie 2. *Nature methods* 2012, 9
431 (4), 357-359.

432 39. Quinlan, A. R.; Hall, I. M., BEDTools: a flexible suite of utilities for comparing genomic features.

433 Bioinformatics **2010**, *26* (6), 841-842.

434